Pharmaceutical segment
Significant increase in operating income - recover from operating losses in the first half of FYE March 2017
Sales

 • Grew sales of new drugs launched last year

 • Received milestone revenues

Costs

 • Sales expenses decreased

Last year - posted one-off contract payment and drug promotion expenses for newly launched drugs

This year - Returned to typical sales expenses

vs. Plan

 • Operating income outperformed

 • Sales underperformed slightly (-1.5%)

Took time for new drugs to penetrate in the market